Merck’s Gardasil is a potent vaccine against HPV, a sexually transmitted disease that can cause cervical cancer. But until recently, cost and production constraints limited its reach. Merck has now committed more than $1 billion to expand capacity, with a focus on underserved countries. Merck more than doubled global supply of Gardasil between 2017 and 2020 and is on track to do so again by 2023.
Courtesy of Merck
As of 4/4/23
Market Value ($M)
Figures are for fiscal year ended Dec. 31, 2022. Market value as of March 17, 2023. Sources: S&P Global; Bloomberg.
Change the World
Prior Year Rank
|Year||Revenues ($M)||Profits ($M)|
Lists ranking Merck
Latest news for Merck
Overwhelmed by a massive outbreak, China authorizes emergency use of Merck COVID pill LagevrioDecember 30, 2022, 10:11 AM UTC
The world’s 10 biggest pharmaceutical companies raked in over $700 billion in revenue in 2021August 15, 2022, 10:15 PM UTC
It’s time for companies to do lessMay 5, 2022, 2:15 PM UTC
The most innovative and inventive drug companies of 2022 set the foundation for success before the pandemicBYSy Mukherjee and IDEA PharmaApril 20, 2022, 9:30 AM UTC